

Yongpeng Ge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8940467/publications.pdf>

Version: 2024-02-01

20
papers

375
citations

1163065
8
h-index

888047
17
g-index

20
all docs

20
docs citations

20
times ranked

437
citing authors

#	ARTICLE	IF	CITATIONS
1	Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies. BMC Pulmonary Medicine, 2022, 22, 14.	2.0	9
2	Clinical heterogeneities and prognoses of patients with myositis specific antibody negative dermatomyositis: a retrospective study in China. Clinical and Experimental Rheumatology, 2022, 40, 284-291.	0.8	2
3	The Clinical Phenotype of Chinese Patients With Autoimmune Pancreatitis Differs Significantly From Western Patients. Frontiers in Medicine, 2022, 9, 771784.	2.6	1
4	Thromboembolic events in idiopathic inflammatory myopathy: a retrospective study in China. Clinical Rheumatology, 2022, , 1.	2.2	2
5	Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis complicated with macrophage activation syndrome. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232210981.	2.5	5
6	Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clinical Rheumatology, 2021, 40, 2311-2317.	2.2	28
7	The effects of infliximab in treating idiopathic inflammatory myopathies: A review article. Dermatologic Therapy, 2021, 34, e14976.	1.7	6
8	Interstitial Lung Disease Is a Major Characteristic of Patients Who Test Positive for Anti-PM/Scl Antibody. Frontiers in Medicine, 2021, 8, 778211.	2.6	6
9	Clinical heterogeneities and prognoses of patients with myositis specific antibody negative dermatomyositis: a retrospective study in China. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
10	Coexistence of Axial Spondyloarthritis and Idiopathic Inflammatory Myopathy. Case Reports in Rheumatology, 2020, 2020, 1-4.	0.6	0
11	Interstitial lung disease is a major characteristic of anti-KS associated ant-synthetase syndrome. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232096841.	2.5	11
12	Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity. Mediators of Inflammation, 2020, 2020, 1-8.	3.0	4
13	Tracheobronchial amyloidosis in primary Sjögren syndrome. Medicine (United States), 2020, 99, e22942.	1.0	1
14	Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome. Clinical Rheumatology, 2020, 39, 2417-2424.	2.2	14
15	The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. Clinical Rheumatology, 2019, 38, 2171-2179.	2.2	41
16	Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Scientific Reports, 2017, 7, 188.	3.3	65
17	The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis. Clinical Rheumatology, 2016, 35, 2715-2721.	2.2	19
18	Clinical Characteristics of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Antibodies in Chinese Patients with Idiopathic Inflammatory Myopathies. PLoS ONE, 2015, 10, e0141616.	2.5	66

#	ARTICLE	IF	CITATIONS
19	The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. Clinical Rheumatology, 2015, 34, 2097-2103.	2.2	47
20	Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clinical Rheumatology, 2015, 34, 99-105.	2.2	48